false
0000883975
0000883975
2026-03-26
2026-03-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 26, 2026
MICROBOT
MEDICAL INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
000-19871 |
|
94-3078125 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
175
Derby St., Bld. 27
Hingham,
MA 02043
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: (781) 875-3605
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.01 par value |
|
MBOT |
|
NASDAQ
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On
March 26, 2026, Microbot Medical Inc. (the “Company”) issued a joint press release with Emory Healthcare, announcing that
Emory Healthcare has successfully completed robotic peripheral endovascular procedures — minimally invasive treatments for certain
vascular conditions — using the Company’s LIBERTY® Endovascular Robotic System. Emory interventional radiologists
have now demonstrated successful use of the LIBERTY System on benign prostatic hyperplasia (BPH, commonly known as enlarged prostate),
as well as liver cancer.
The
press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information
in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be
deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
Number |
|
Description |
| |
|
|
| 99.1 |
|
Press Release |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
| |
MICROBOT
MEDICAL INC. |
| |
|
| |
By: |
/s/
Harel Gadot |
| |
Name: |
Harel
Gadot |
| |
Title: |
Chief
Executive Officer, President and Chairman |
Date:
March 26, 2026
Exhibit 99.1
Emory
Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s
LIBERTY® Endovascular Robotic System
World’s
first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization
mapping for liver cancer are among the robotic cases performed using the LIBERTY System, demonstrating system adoption across multiple
case types
March
26, 2026
Atlanta,
GA and Hingham, MA. – March 26, 2026 - Emory Healthcare has successfully completed robotic peripheral endovascular procedures
— minimally invasive treatments for certain vascular conditions — using Microbot Medical’s (Nasdaq:
MBOT) LIBERTY® Endovascular Robotic System. Microbot believes that the application of the single-use robotic system
can expand patient access to high-quality care. Emory interventional radiologists have now demonstrated successful use of the LIBERTY
System on benign prostatic hyperplasia (BPH, commonly known as enlarged prostate), as well as liver cancer.
With
the LIBERTY System, Emory’s physicians performed the first robotic prostate artery embolization or (PAE), a minimally invasive,
image-guided outpatient procedure to treat BPH. Published research has shown that BPH affects approximately 40 million men in the U.S.
“I’m
excited to be part of the first team performing the robotic PAE with the LIBERTY system at Emory,” says Zachary L. Bercu, MD, an
interventional radiologist with Emory Healthcare and professor in the Division of Interventional Radiology and Image-Guided Medicine
at Emory University School of Medicine. “Using the new system for PAE assists in navigating and handling challenging anatomy with
precision. I believe that it represents a significant advancement in how interventional radiologists will approach prostate artery embolization.”
Bercu
and a team of specialists also completed the first robotic Yttrium-90 or Y-90 radioembolization mapping for liver cancer at Emory—using
the same hand-held robotic system. “The endovascular robotic procedure allows specialists
to develop personalized care for liver cancer, steering precisely to the target to deliver a nuanced treatment for each patient,”
says Bercu.
“With
a sizeable patient population, we believe that LIBERTY can establish endovascular robotic navigation as the standard of care for PAE
in patients with enlarged prostates, mirroring how robotic-assisted prostatectomy became the dominant surgical approach for prostate
cancer,” says Harel Gadot, Microbot Medical Chairman, CEO & President. “The successful completion of LIBERTY’s
cases at Emory reinforces our confidence in the innovation and benefits it can bring to clinicians, patients and procedural workflow.”
Robotic
Prostate Artery Embolization or (PAE) for BPH
PAE
works to shrink the prostate by blocking its blood supply, improving lower urinary tract symptoms.
Using the LIBERTY® Endovascular Robotic System for PAE, it has been shown to improve
efficiency to reach the treatment site inside the blood vessels, because of its allowance of fine motor control.
Y-90
for liver cancer
Precision
mapping using the LIBERTY System assists clinicians to visualize the blood vessel in advance of the treatment. Once mapping is completed,
tiny beads containing the radioactive isotope yttrium-90 are injected inside the blood vessels
that feed a tumor, wedging in blood vessels supplying the cancer cells and delivering a high dose of radiation to the tumor while sparing
normal tissue.
The
LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic system for peripheral
endovascular procedures, and is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain
and improve procedure efficiency.
Microbot
Medical commenced the Limited Market Release of the LIBERTY
system in November 2025 and plans for a Full Market Release at the Society of Interventional Radiology
conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.
About
Emory Healthcare
Emory
Healthcare, with 29,500 employees and 11 hospitals, is the most comprehensive academic health system in Georgia. System-wide, it has
3,028 licensed patient beds, more than 3,800 physicians practicing in more than 70 specialties, serving metro Atlanta and Georgia. It
also provides services to greater Georgia through a joint venture at St. Francis–Emory Healthcare in Columbus, six regional affiliate
hospitals and its clinically integrated physician network.
About
Microbot Medical
Microbot
Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through
advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared
single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property
portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn
more at www.microbotmedical.com and connect on LinkedIn and X.
Microbot
Medical’s Safe Harbor
Statements
to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development,
commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including,
but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,”
“intends,” “may,” “might,” “possible,” “potential,” “predicts,”
“projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties,
including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular
Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory
pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes
in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from
new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual
property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors”
in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s
web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements,
except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
Janet
Christenbury, Emory Healthcare
janet.christenbury@emoryhealthcare.org
